A phase 3 study, the REPRIEVE trial, has unveiled promising results that could have a far-reaching impact on patients living with human immunodeficiency virus (HIV). The trial, aiming to determine if statin therapy could prevent major adverse cardiovascular events in HIV-positive individuals undergoing antiretroviral therapy, demonstrates a 35% relative reduction in cardiovascular risk with daily pitavastatin calcium compared to placebo therapy.
While the world has been focused on combating the HIV epidemic over the past five decades, a lesser-known yet persistent risk has been lurking in the shadows: the threat of cardiovascular disease events among those diagnosed with HIV. Presented at the 12th International AIDS Society Conference on HIV Science, the REPRIEVE trial was initiated to address this gap in knowledge and explore the potential of statin therapy in mitigating cardiovascular risk for HIV patients.
Led by Steven Grinspoon, MD, from Massachusetts General Hospital, the phase 3 trial enlisted participants aged 40 to 75 years with diagnosed HIV infections and stable antiretroviral therapy. All participants had a low-to-moderate risk of atherosclerotic cardiovascular disease, as determined by established risk calculators. A total of 10,865 individuals from 12 countries underwent screening, with 7,769 ultimately randomized into two groups: one receiving 4 mg per day of oral pitavastatin calcium, and the other an identical placebo therapy.
After a median follow-up of 5.1 years, the trial was halted early due to the remarkable efficacy observed in the pitavastatin group. The rate of major adverse cardiovascular events was found to be 4.81 per 1000 person-years in the pitavastatin group, compared to 7.32 per 1000 person-years in the placebo group. This resulted in a statistically significant hazard ratio of 0.65, denoting a 35% relative reduction in cardiovascular risk. The effect of pitavastatin remained consistent across subgroups, with some variations based on hypertension status.
The findings of the REPRIEVE trial underscore the importance of cardiovascular disease prevention measures for patients with HIV. While pitavastatin targets critical risk factors such as LDL cholesterol and systemic inflammation, the trial’s editorial writer, Matthew Freiberg, MD, emphasizes the necessity of addressing other risk factors, including obesity, smoking, diabetes, and alcohol use. A comprehensive preventive approach can yield transformative results in reducing cardiovascular risk among HIV patients.
The REPRIEVE trial has provided a glimmer of hope in the fight against cardiovascular disease among individuals living with HIV. The groundbreaking results, indicating a 35% relative reduction in risk with pitavastatin therapy, hold the potential to revolutionize preventive measures for this vulnerable patient population. As the medical community delves deeper into this discovery, it becomes clear that a holistic approach to cardiovascular health is imperative for those living with HIV.
